Speckhart Susan Ashley
Maine Children's Cancer Program, Scarborough, Maine, USA.
Pediatr Blood Cancer. 2023 Apr;70(4):e30133. doi: 10.1002/pbc.30133. Epub 2023 Jan 5.
Long-term seroprotection against the measles and mumps viruses has not been reported in childhood cancer survivor (CCS) who received two-lifetime doses of the measles, mumps, and rubella (MMR) vaccine. We performed a retrospective study of measles and mumps titers among 55 CCS who received standard chemotherapy and two MMR vaccinations at any time. Over 75% of CCS who received at least one MMR prior to their cancer diagnosis had a negative or equivocal titer to measles or mumps. In contrast, all CCS who received the MMR series following their cancer treatment demonstrated long-term seroprotection to both viruses at a mean of 8.2 years after their last vaccination.
在接受过两剂次麻疹、腮腺炎和风疹（MMR）疫苗的儿童癌症幸存者（CCS）中，尚未有长期抗麻疹和腮腺炎病毒血清保护作用的报道。我们对55名接受标准化疗且在任何时间接种过两剂MMR疫苗的CCS进行了麻疹和腮腺炎抗体滴度的回顾性研究。超过75%在癌症诊断前至少接种过一剂MMR的CCS对麻疹或腮腺炎的抗体滴度呈阴性或不确定。相比之下，所有在癌症治疗后接种MMR系列疫苗的CCS在最后一次接种疫苗后平均8.2年时对这两种病毒均表现出长期血清保护作用。
